News
March 18, 2019
Study Evaluates Two Drug Therapies on Children with Lupus Nephritis
Today, lupus treatment in children is based on research conducted on adults. A new study analyzed treatment response, damage accrual, and disease activity in 51 children (16 years old or younger) with juvenile-onset lupus nephritis. The study analyzed data collected from juveniles who were treated with mycophenolate mofetil (a drug that prevents organ rejection) or cyclophosphamide (a drug used to treat nephrotic syndrome). While there were no statistically significant differences identified between the two therapies, researchers concluded that further study should include children with ethnically diverse backgrounds. Ultimately, more research in children with lupus nephritis is needed. Learn about lupus and children.
See More:
The latest from Inside Lupus Research
News
Neighborhood Disadvantage Associated with Lower Testing and Physician Access in Young People with Systemic Lupus Erythematosus Despite Insurance Coverage
News
Drug Update: First Person Dosed with Investigational Therapy AlloNK for Lupus Nephritis
News
Potential New Diagnostic and Disease Monitoring Biomarker for Systemic Lupus Erythematosus Found in B Cells
News
FDA Approves a Phase 1 Trial for Investigational Therapy, CB-010, for Lupus Nephritis Treatment